Last $156.99 USD
Change Today -0.54 / -0.34%
Volume 46.3K
PRGO On Other Exchanges
Symbol
Exchange
Tel Aviv
Frankfurt
As of 10:00 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$157.11
Previous Close
$157.00
Day High
$157.50
Day Low
$156.72
52 Week High
01/9/15 - $172.00
52 Week Low
05/8/14 - $125.37
Market Cap
22.1B
Average Volume 10 Days
899.9K
EPS TTM
$3.33
Shares Outstanding
140.8M
EX-Date
02/25/15
P/E TM
47.3x
Dividend
$0.50
Dividend Yield
0.27%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 10/1/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Company plc Launches AB Therapeutic Equivalent Testosterone

Perrigo Company plc announced that it has launched its AB therapeutic equivalent testosterone gel 1.0%. The Food and Drug Administration (FDA) concluded previously that Perrigo's testosterone product is therapeutically equivalent to AbbVie's AndroGel 1.0% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1.0% when used under the conditions specified in the labeling. Androgel 1.0% (testosterone gel 1.0%) is indicated to treat adult males who have low or no testosterone.

Perrigo Company plc Signs Supply Agreement with Ferrara

Perrigo Company plc and Ferrara Candy Company Inc. announced that Perrigo's Nutritionals division has signed a supply agreement with Ferrara to manufacture store brand gummy vitamins and dietary supplements to be sold at leading retailers across the United States. The five-year supply agreement gives Perrigo exclusivity on a full line of store brand gummy vitamin, mineral and supplement products using Ferrara's gummy technology and manufacturing capabilities. The company’s extensive expertise in vitamin and dietary supplement formulation, quality assurance, and safety testing will be combined with Ferrara's manufacturing capabilities and non-stick gummy technology, which excels in gummy taste, texture and packaging. In addition to being suitable for vitamins and dietary supplements, Ferrara's gummy technology has the potential for other over-the-counter (OTC) products as well.

Perrigo Company plc Launches Clobetasol Propionate Spray

Perrigo Company plc announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex Spray, 0.05%. The company was the first generic filer against this product and it is entitled to 180 days of generic exclusivity. The launch date was agreed upon in a litigation settlement between Perrigo and Galderma Laboratories, L.P. Clobetasol propionate spray, 0.05% is indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in adults 18 years of age or older and 52-week sales of the product were approximately $100 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $156.99 USD -0.54

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,212 INR -137.20
Endo International PLC $79.13 USD -0.02
Hospira Inc $66.13 USD -0.375
Mead Johnson Nutrition Co $97.27 USD -0.87
Mylan Inc/PA $56.15 USD -0.65
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 5.2x
Price/Book 2.4x
Price/Cash Flow 116.2x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.